No, Omnitrope Is Not the Same as Norditropin
Omnitrope and Norditropin are both recombinant human growth hormone (somatropin) products used to treat growth hormone deficiency in children and adults, but they differ in manufacturing, branding, and regulatory status. Omnitrope is the first FDA-approved somatropin biosimilar, referencing Norditropin (and Genotropin) as originator products.[1]
How Do They Compare in Formulation and Delivery?
Omnitrope comes as a prefilled cartridge or vial for injection via pen device or syringe. Norditropin uses NordiFlex or NordiPen delivery systems with liquid formulation for easier subcutaneous injection. Both deliver the same active ingredient—somatropin—but Omnitrope's biosimilar process allows slight differences in non-proprietary excipients like preservatives.[1][2]
Why Is Omnitrope Cheaper?
Omnitrope costs 20-40% less than Norditropin due to its biosimilar status, which requires demonstrating similarity (not identical replication) to the reference product. This lowers development barriers compared to Norditropin's patented originator status.[1]
When Does Norditropin's Patent Protection End?
Key U.S. patents on Norditropin (somatropin-specific formulations and devices) expired around 2019-2023, enabling biosimilars like Omnitrope. Check DrugPatentWatch.com for exact expiry dates and ongoing litigation on remaining patents like delivery pens.[3]
Can Patients Switch Between Them?
Yes, clinical studies show no significant differences in efficacy or safety for switching from Norditropin to Omnitrope. Both achieve similar IGF-1 levels and growth outcomes, though doctors monitor for individual responses.[1][2]
Common Side Effects Patients Report
Patients on either report similar issues: injection site reactions, headache, joint pain, and fluid retention. Omnitrope's biosimilar trials confirmed comparable safety profiles to Norditropin.[1]
Sources:
[1] FDA Approval Summary for Omnitrope (biosimilar to Norditropin/Genotropin): https://www.fda.gov/drugs/biosimilars/omnitrope
[2] European Medicines Agency Assessment Report: https://www.ema.europa.eu/en/medicines/human/EPAR/omnitrope
[3] DrugPatentWatch.com - Norditropin Patents: https://www.drugpatentwatch.com/p/tradename/NORDITROPIN